![Mark Sims](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark Sims is currently Chief Commercial Officer at Candel Therapeutics, Inc. Formerly, Mr. Sims was VP & Global Franchise Head-EGFRm Lung Cancer at AstraZeneca PLC.
Education includes an MBA from Thunderbird School of Global Management and an undergraduate degree from McMaster University.
| Unternehmen | Position | Beginn |
|---|---|---|
| CANDEL THERAPEUTICS, INC. | Corporate Officer/Principal | 06.07.2026 |
| Unternehmen | Position | Ende |
|---|---|---|
| ASTRAZENECA PLC | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 4 |
|---|---|
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Thunderbird School of Global Management
 Thunderbird School of Global Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
McMaster University
 McMaster University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Candel Therapeutics, Inc.
 Candel Therapeutics, Inc. BiotechnologyHealth Technology Develops and distributes immunotherapies for the treatment of cancer | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
Wählen Sie MarketScreener 
